Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du Sells 7,013 Shares of Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 7,013 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $17.48, for a total value of $122,587.24. Following the transaction, the chief executive officer now owns 1,081,910 shares in the company, valued at $18,911,786.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ying Du also recently made the following trade(s):

• On Wednesday, June 26th, Ying Du sold 23,939 shares of Zai Lab stock. The shares were sold at an average price of $17.90, for a total value of $428,508.10.

Zai Lab Trading Up 0.5 %

Shares of ZLAB stock opened at $17.37 on Wednesday. Zai Lab Limited has a fifty-two week low of $13.48 and a fifty-two week high of $32.60. The business’s 50 day moving average price is $18.45 and its 200-day moving average price is $19.89.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.38. Zai Lab had a negative net margin of 116.45% and a negative return on equity of 40.21%. The business had revenue of $87.15 million for the quarter, compared to analysts’ expectations of $77.07 million. During the same quarter in the previous year, the business posted ($0.51) earnings per share. On average, equities research analysts expect that Zai Lab Limited will post -2.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zai Lab

Several hedge funds and other institutional investors have recently modified their holdings of ZLAB. Capital World Investors boosted its position in Zai Lab by 8.9% during the 1st quarter. Capital World Investors now owns 5,684,180 shares of the company’s stock valued at $91,061,000 after acquiring an additional 465,337 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Zai Lab by 177.6% during the fourth quarter. Wellington Management Group LLP now owns 5,336,457 shares of the company’s stock valued at $145,845,000 after purchasing an additional 3,413,829 shares in the last quarter. Janus Henderson Group PLC grew its stake in Zai Lab by 9.6% in the first quarter. Janus Henderson Group PLC now owns 4,428,011 shares of the company’s stock worth $70,924,000 after purchasing an additional 387,729 shares during the period. Bamco Inc. NY raised its holdings in Zai Lab by 7.3% in the first quarter. Bamco Inc. NY now owns 1,599,865 shares of the company’s stock worth $25,630,000 after purchasing an additional 108,991 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its position in Zai Lab by 1.2% during the third quarter. Rock Springs Capital Management LP now owns 1,237,023 shares of the company’s stock valued at $30,072,000 after buying an additional 14,600 shares during the period. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $64.57.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.